Spots Global Cancer Trial Database for Utility of Perfusion MRI to Detect Radiation Necrosis in Patients With Brain Metastases

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Utility of Perfusion MRI to Detect Radiation Necrosis in Patients With Brain Metastases

Official Title: Diagnostic Accuracy of Dynamic Susceptibility Contrast (DSC) Perfusion MRI to Determine Radiation Necrosis Versus Tumor Progression in Brain Metastases Treated With Stereotactic Radiosurgery

Study ID: NCT03680144

Conditions

Invasive Malignant Neoplasm

Metastatic Malignant Neoplasm in the Brain

Interventions

Dynamic Susceptibility Contrast-MRI (DSC-MRI)

Magnetic Resonance Imaging (MRI)

Study Description

Brief Summary: This trial studies how well dynamic susceptibility contrast-magnetic resonance imaging (MRI) works in determining radiation necrosis and tumor progression in participants with cancer that has spread to the brain and are being treated with radiation therapy. Diagnostic procedures, such as dynamic susceptibility contrast-MRI, may improve the ability to determine indeterminate post-treatment changes seen on imaging after radiation therapy.

Detailed Description: PRIMARY OBJECTIVE: I. To prospectively determine the sensitivity and specificity of dynamic susceptibility contrast (DSC)-MRI parameters in detecting tumor recurrence versus radiation necrosis for brain metastases treated with stereotactic radiosurgery (SRS). SECONDARY OBJECTIVES: I. To correlate radiographic diagnoses with pathologic diagnoses when surgical resection is clinically indicated. II. To correlate baseline relative cerebral blood volume (rCBV) values and other hemodynamic parameters with tumor primary histology. III. To assess overall survival, local failure, distant brain failure and neurologic death. OUTLINE: Participants undergo a diagnostic MRI with and without contrast and treatment planning DSC perfusion MRI series before receiving SRS at 4-6 weeks after SRS, and then every 3 months unless clinically indicated sooner.